UB Paderborn / Katalog / Suche / in CDI

Histology-agnostic drug development - considering issues beyond the tissue

Nature reviews. Clinical oncology, 2020-09, Vol.17 (9), p.555-568

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Clinical cancer research, 2019-10, Vol.25 (20), p.6107-6118

2019

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

Oncology (Williston Park, N.Y.), 2021-12, Vol.35 (12), p.794-803

2021

Link zum Volltext

Verfügbarkeit prüfen

Mouse Cardiac Acyl Coenzyme A Synthetase 1 Deficiency Impairs Fatty Acid Oxidation and Induces Cardiac Hypertrophy

Molecular and Cellular Biology, 2011-03, Vol.31 (6), p.1252-1262

2011

Link zum Volltext

Verfügbarkeit prüfen

Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets

Cancers, 2019-08, Vol.11 (9), p.1283

2019

Link zum Volltext

Verfügbarkeit prüfen

Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results

Journal of Immunotherapy and Precision Oncology, 2020-05, Vol.3 (2), p.83-89

2020

Link zum Volltext

Verfügbarkeit prüfen

1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1755-A1755

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeted Metabolic Imaging to Improve the Management of Heart Disease

JACC. Cardiovascular imaging, 2012-02, Vol.5 (2), p.214-226

2012

Link zum Volltext

Verfügbarkeit prüfen

Glucose Regulation of Load‐Induced mTOR Signaling and ER Stress in Mammalian Heart

Journal of the American Heart Association, 2013-06, Vol.2 (3), p.e004796-n/a

2013

Link zum Volltext

Verfügbarkeit prüfen

Return to the fetal gene program: a suggested metabolic link to gene expression in the heart

Annals of the New York Academy of Sciences, 2010-02, Vol.1188 (1), p.191-198

2010

Link zum Volltext

Verfügbarkeit prüfen

762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A857-A857

2023

Link zum Volltext

Verfügbarkeit prüfen

756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A852-A852

2023

Link zum Volltext

Verfügbarkeit prüfen

Screening for Phase 1 Clinical Trials: An Opportunity to Evaluate Psychological States and Reeducate Patients on Prognosis?

Oncology (Williston Park, N.Y.), 2020-09, Vol.34 (9), p.367-369

2020

Link zum Volltext

Verfügbarkeit prüfen

Return to the fetal gene program

Annals of the New York Academy of Sciences, 2010-02, Vol.1188 (1), p.191-198

2010

Link zum Volltext

Verfügbarkeit prüfen

Patient-Centered, Physician-Investigator Friendly Pragmatic Phase I/II Trial Designs—The 4P Model

Mayo Clinic proceedings, 2020-11, Vol.95 (11), p.2566-2568

2020

Link zum Volltext

Verfügbarkeit prüfen

Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designsd The 4P Model

Mayo Clinic proceedings, 2020-11, Vol.95 (11), p.2566-2568

2020

Link zum Volltext

Verfügbarkeit prüfen

Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy

American journal of physiology. Heart and circulatory physiology, 2004-03, Vol.286 (3), p.H1185-H1192

2004

Link zum Volltext

Verfügbarkeit prüfen

Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs-The 4P Model

Mayo Clinic proceedings, 2020-11, Vol.95 (11), p.2566-2568

2020

Link zum Volltext

Verfügbarkeit prüfen

Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2537-2537

2017

Link zum Volltext

Verfügbarkeit prüfen

Remodeling of Glucose Metabolism Precedes Pressure Overload-Induced Left Ventricular Hypertrophy: Review of a Hypothesis

Cardiology, 2015-01, Vol.130 (4), p.211-220

2015

Link zum Volltext

Verfügbarkeit prüfen

Everything Points to Myeloma

Journal of general internal medicine : JGIM, 2015-06, Vol.30 (6), p.855-855

2015

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors and Outcomes in Primary Effusion Lymphoma in HIV-Infected Patients: A Single Center Experience

Blood, 2014-12, Vol.124 (21), p.5415-5415

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS11573-TPS11573

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3663-TPS3663

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians

Oncology (Williston Park, N.Y.), 2021-05, Vol.35 (5), p.244-248

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Histology-agnostic drug development - considering issues beyond the tissue

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

Mouse Cardiac Acyl Coenzyme A Synthetase 1 Deficiency Impairs Fatty Acid Oxidation and Induces Cardiac Hypertrophy

Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets

Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results

1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

Targeted Metabolic Imaging to Improve the Management of Heart Disease

Glucose Regulation of Load‐Induced mTOR Signaling and ER Stress in Mammalian Heart

Return to the fetal gene program: a suggested metabolic link to gene expression in the heart

762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors

756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

Screening for Phase 1 Clinical Trials: An Opportunity to Evaluate Psychological States and Reeducate Patients on Prognosis?

Return to the fetal gene program

Patient-Centered, Physician-Investigator Friendly Pragmatic Phase I/II Trial Designs—The 4P Model

Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designsd The 4P Model

Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy

Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs-The 4P Model

Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types

Remodeling of Glucose Metabolism Precedes Pressure Overload-Induced Left Ventricular Hypertrophy: Review of a Hypothesis

Everything Points to Myeloma

Prognostic Factors and Outcomes in Primary Effusion Lymphoma in HIV-Infected Patients: A Single Center Experience

A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma

A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET

Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians

Suchergebnisse filtern